MCID: OVR114
MIFTS: 62

Ovarian Cancer 1

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 57 29
Ovarian Carcinoma 12 13 55 15 73
Ovarian Cancer, Susceptibility to 57 13
Ovarian Cancer, Susceptibility to, 1 57
Malignant Neoplasm of Ovary 73
Ovarian Epithelial Cancer 44
Epithelial Ovarian Cancer 73
Cancer, Ovarian 40
Ovarian Cancer 57
Ovcas1 57

Classifications:



External Ids:

OMIM 57 607893
Disease Ontology 12 DOID:4001
MeSH 44 C538090
NCIt 50 C4908

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian carcinoma, is related to breast-ovarian cancer, familial 1 and hereditary breast ovarian cancer syndrome, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is OVCAS1 (Ovarian Cancer, Epithelial, Susceptibility To), and among its related pathways/superpathways are TGF-Beta Pathway and PI3K-Akt signaling pathway. The drugs CEA-Scan and Doxil have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and t cells, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Description from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Ovarian Benign Neoplasm

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 531)
# Related Disease Score Top Affiliating Genes
1 breast-ovarian cancer, familial 1 34.1 BRCA1 BRCA2
2 hereditary breast ovarian cancer syndrome 34.1 BRCA1 BRCA2 TP53
3 ovarian cancer 33.7 BRCA1 BRCA2 CDH1 DPH1 ERBB2 FILIP1L
4 hereditary site-specific ovarian cancer syndrome 33.5 BRCA1 BRCA2
5 ovarian clear cell carcinoma 32.4 ARID1A HNF1B KRT7 PIK3CA TP53
6 ovarian disease 32.1 BRCA1 BRCA2 TP53 VEGFA
7 granulosa cell tumor of the ovary 31.7 ERBB2 KRT7 TP53
8 pancreatic cancer 31.7 AREG BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
9 breast cancer 31.6 AREG BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
10 adenocarcinoma 30.5 CDH1 ERBB2 PIK3CA TP53 VEGFA
11 fallopian tube carcinoma 30.5 BRCA1 BRCA2 ERBB2 TP53 VEGFA
12 primary peritoneal carcinoma 30.4 BRCA1 BRCA2 ERBB2 TP53 VEGFA
13 carcinosarcoma 30.3 ERBB2 KRT7 PIK3CA TP53
14 ovary epithelial cancer 30.1 AREG ARID1A BRCA1 BRCA2 CDH1 CEACAM5
15 papillary carcinoma 30.1 CDH1 ERBB2 KRT7 PAX8
16 li-fraumeni syndrome 30.0 BRCA1 BRCA2 TP53
17 clear cell adenocarcinoma 30.0 ARID1A HNF1B KRT7 PAX8
18 endocervical adenocarcinoma 30.0 KRT7 PAX8 TP53
19 small cell cancer of the lung 30.0 CEACAM5 KRT7 PIK3CA TP53
20 cervical cancer 30.0 CDH1 ERBB2 PIK3CA TP53 VEGFA
21 endosalpingiosis 29.9 KRT7 PAX8
22 papillary serous adenocarcinoma 29.8 BRCA1 KRT7 TP53
23 renal cell carcinoma, nonpapillary 29.8 CDH1 HNF1B KRT7 PAX8 VEGFA
24 cervical adenocarcinoma 29.8 ERBB2 KRT7 TP53
25 glioblastoma 29.8 BRCA2 ERBB2 PIK3CA TP53 VEGFA
26 ovarian serous cystadenocarcinoma 29.8 ERBB2 PIK3CA TP53
27 prostate cancer 29.8 BRCA1 BRCA2 CDH1 ERBB2 HNF1B PIK3CA
28 sporadic breast cancer 29.8 BRCA1 BRCA2 ERBB2 TP53
29 lung cancer 29.8 AREG CDH1 CEACAM5 ERBB2 KRT7 PIK3CA
30 uterine corpus serous adenocarcinoma 29.7 BRCA1 ERBB2 PIK3CA TP53
31 wilms tumor 1 29.7 AREG BRCA2 ERBB2 KRT7 PAX8 TP53
32 in situ carcinoma 29.7 BRCA1 CDH1 ERBB2 TP53
33 serous cystadenocarcinoma 29.7 ERBB2 PIK3CA TP53 VEGFA
34 cowden disease 29.7 BRCA1 BRCA2 PIK3CA
35 transitional cell carcinoma 29.7 CDH1 ERBB2 KRT7 TP53
36 breast carcinoma in situ 29.6 BRCA1 BRCA2 ERBB2 TP53 VEGFA
37 colorectal cancer 29.6 AREG BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
38 cystadenocarcinoma 29.6 CEACAM5 ERBB2 KRT7 PIK3CA TP53 VEGFA
39 endometrial cancer 29.6 AREG BRCA1 BRCA2 CDH1 ERBB2 KRT7
40 squamous cell carcinoma 29.6 CDH1 ERBB2 PIK3CA TP53 VEGFA
41 glioma 29.6 BRCA2 ERBB2 PIK3CA TP53 VEGFA
42 papillary adenocarcinoma 29.5 CDH1 CEACAM5 ERBB2 KRT7 TP53
43 gallbladder cancer 29.5 CDH1 CEACAM5 ERBB2 PIK3CA TP53
44 krukenberg carcinoma 29.5 HNF1B KRT7
45 squamous cell carcinoma, head and neck 29.4 AREG CDH1 ERBB2 PIK3CA TP53 VEGFA
46 cholangiocarcinoma 29.4 CDH1 CEACAM5 ERBB2 KRT7 PIK3CA TP53
47 lung cancer susceptibility 3 29.2 CDH1 CEACAM5 ERBB2 KRT7 PIK3CA TP53
48 ovary adenocarcinoma 29.2 ARID1A CEACAM5 ERBB2 ESS2 HNF1B KRT7
49 pancreas adenocarcinoma 29.0 AREG BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
50 breast-ovarian cancer, familial 2 12.4

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM:

607893

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.36 ARID1A BRCA1 BRCA2 CDH1 ERBB2 HNF1B

MGI Mouse Phenotypes related to Ovarian Cancer 1:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.3 ARID1A BRCA1 BRCA2 CDH1 DPH1 ERBB2
2 endocrine/exocrine gland MP:0005379 10.26 AREG ARID1A BRCA1 BRCA2 CDH1 ERBB2
3 homeostasis/metabolism MP:0005376 10.25 AREG ARID1A BRCA1 BRCA2 CDH1 DPH1
4 embryo MP:0005380 10.24 ARID1A BRCA1 BRCA2 CDH1 DPH1 ERBB2
5 growth/size/body region MP:0005378 10.23 AREG ARID1A BRCA1 BRCA2 CDH1 DPH1
6 mortality/aging MP:0010768 10.13 AREG ARID1A BRCA1 BRCA2 CDH1 DPH1
7 digestive/alimentary MP:0005381 10.11 AREG BRCA1 BRCA2 CDH1 DPH1 ERBB2
8 integument MP:0010771 10.06 AREG BRCA1 BRCA2 CDH1 DPH1 ERBB2
9 limbs/digits/tail MP:0005371 9.91 BRCA1 BRCA2 DPH1 ERBB2 PAX8 TP53
10 neoplasm MP:0002006 9.91 ARID1A BRCA1 BRCA2 CDH1 DPH1 ERBB2
11 no phenotypic analysis MP:0003012 9.7 ARID1A CDH1 ESS2 PAX8 PIK3CA TP53
12 reproductive system MP:0005389 9.7 AREG ARID1A BRCA1 BRCA2 CDH1 ERBB2
13 skeleton MP:0005390 9.28 ARID1A BRCA1 BRCA2 DPH1 ERBB2 PAX8

Drugs & Therapeutics for Ovarian Cancer 1

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
CEA-Scan 18 Immunomedics April 1996
2
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
3
Ethyol 18 AMIFOSTINE Alza December 8, 1995
4
Hycamtin 18 49 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/May 1996
5
Iressa 18 49 GEFITINIB AstraZeneca May 2003
6
Lynparza 18 49 OLAPARIB AstraZeneca December 2014

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Violence Against Women and Consequences During Climacteric´s Phase Completed NCT01028118 Phase 3

Search NIH Clinical Center for Ovarian Cancer 1

Cochrane evidence based reviews: ovarian epithelial cancer

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 29

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

41
Ovary, Endothelial, T Cells, Testes, Lymph Node, Lung, Bone

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 2585)
# Title Authors Year
1
RGS5 decreases the proliferation of human ovarian carcinoma‑derived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia. ( 30365142 )
2019
2
Antrodia salmonea-induced oxidative stress abrogates HER-2 signaling cascade and enhanced apoptosis in ovarian carcinoma cells. ( 30146791 )
2019
3
The role of the long non-coding RNA TDRG1 in epithelial ovarian carcinoma tumorigenesis and progression through miR-93/RhoC pathway. ( 28984384 )
2018
4
P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling. ( 29343281 )
2018
5
TLR4 and NFI_B signaling is critical for taxol resistance in ovarian carcinoma cells. ( 28771725 )
2018
6
Clitoral priapism due to distant clitoral metastasis of high-grade serous ovarian carcinoma: A case report and review of the literature. ( 29915806 )
2018
7
Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma. ( 29423077 )
2018
8
Pseudocirrhosis in a Patient with New-Onset Dysphagia and History of Ovarian Carcinoma. ( 29670925 )
2018
9
Unfolded protein response, a link between endometrioid ovarian carcinoma and endometriosis: A pilot study. ( 30250617 )
2018
10
Forearm myo-fasciitis and arthritis in a female with metastatic ovarian carcinoma. ( 29608760 )
2018
11
Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted. ( 30364622 )
2018
12
Myelodysplastic Syndrome After Olaparib Treatment in Heavily Pretreated Ovarian Carcinoma. ( 30212381 )
2018
13
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network. ( 30428389 )
2018
14
Natural killer cells inhibit metastasis of ovarian carcinoma cells and show therapeutic effects in a murine model of ovarian cancer. ( 30116358 )
2018
15
Para-aortic paraganglioma mimicking lymph node metastasis in an ovarian carcinoma: a case report. ( 29536750 )
2018
16
Early stage ovarian carcinoma with symptoms mimicking tuberculous peritonitis in a postmenopausal woman: A case report. ( 30290652 )
2018
17
Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report. ( 30555799 )
2018
18
Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma. ( 29926183 )
2018
19
Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative. ( 30243588 )
2018
20
The circular RNA circ-ITCH suppresses ovarian carcinoma progression through targeting miR-145/RASA1 signaling. ( 30243714 )
2018
21
Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation. ( 30246138 )
2018
22
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. ( 30249526 )
2018
23
Cerebellar Metastasis From Ovarian Carcinoma Harboring PIK3CA-Activating Mutation: A "Clear" Explanation for an Unexpected "Vertigo". ( 30252727 )
2018
24
Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. ( 30253737 )
2018
25
Immunohistochemical Characterization Improves the Reproducibility of the Histological Diagnosis of Ovarian Carcinoma ( 30256049 )
2018
26
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. ( 30266954 )
2018
27
METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells. ( 30274262 )
2018
28
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ( 30285216 )
2018
29
Chemotherapeutic Efficacy of Implantable Antineoplastic-Treatment Protocols in an Optimal Mouse Model for Human Ovarian Carcinoma Cell Targeting. ( 30287783 )
2018
30
APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. ( 30289149 )
2018
31
Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells. ( 30335544 )
2018
32
Inhibition of store-operated channels by carboxyamidotriazole sensitizes ovarian carcinoma cells to anti-BclxL strategies through Mcl-1 down-regulation. ( 30338034 )
2018
33
Ovarian Carcinoma-Associated Mesenchymal Stem Cells Arise from Tissue-Specific Normal Stroma. ( 30353617 )
2018
34
Low-grade Serous Ovarian Carcinoma. ( 30364401 )
2018
35
Epithelial Ovarian Carcinoma Associated with Metastases to Central Nervous System: Two Case Reports. ( 30386663 )
2018
36
Risk Factors for Ovarian Carcinoma. ( 30390763 )
2018
37
Ovarian carcinoma biological nanotherapy: Comparison of the advantages and drawbacks of lipid, polymeric, and hybrid nanoparticles for cisplatin delivery. ( 30399584 )
2018
38
Effects of let-7c on the proliferation of ovarian carcinoma cells by targeted regulation of CDC25a gene expression. ( 30405749 )
2018
39
Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. ( 30412078 )
2018
40
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. ( 30425037 )
2018
41
Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma. ( 30428884 )
2018
42
Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma. ( 30445726 )
2018
43
Immunophenotypic profile as predictor of prognosis in advanced ovarian carcinoma. ( 30448218 )
2018
44
High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma. ( 30448219 )
2018
45
Morphological changes in the ovarian carcinoma cells of Wistar rats induced by chemotherapy with cisplatin and dioxadet. ( 30460164 )
2018
46
Protein tyrosine phosphatase L1 inhibits high-grade serous ovarian carcinoma progression by targeting IκBα. ( 30464509 )
2018
47
Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma. ( 30467600 )
2018
48
Diagnostic Value of a Group of MicroRNA Genes Hypermethylated in Ovarian Carcinoma. ( 30488208 )
2018
49
Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. ( 30501904 )
2018
50
Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. ( 30526667 )
2018

Variations for Ovarian Cancer 1

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

Pathways related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.4 AREG BRCA1 CDH1 ERBB2 HNF1B PIK3CA
2
Show member pathways
12.87 AREG BRCA1 ERBB2 PIK3CA TP53 VEGFA
3 12.59 BRCA2 CDH1 ERBB2 PAX8 PIK3CA TP53
4
Show member pathways
12.47 BRCA1 BRCA2 CDH1 ERBB2 PIK3CA TP53
5
Show member pathways
12.41 AREG CDH1 ERBB2 PIK3CA TP53
6 12.37 BRCA1 ERBB2 PIK3CA TP53 VEGFA
7
Show member pathways
12.37 ARID1A BRCA1 BRCA2 CDH1 ERBB2 PIK3CA
8
Show member pathways
12.32 AREG ERBB2 PIK3CA TP53 VEGFA
9
Show member pathways
12.3 AREG BRCA2 CDH1 ERBB2 PAX8 PIK3CA
10 12.28 CDH1 HNF1B PSMA2 TP53
11 12.16 ERBB2 PIK3CA TP53 VEGFA
12 11.95 BRCA1 BRCA2 CDH1 TP53 VEGFA
13 11.77 ERBB2 PIK3CA VEGFA
14
Show member pathways
11.67 BRCA1 BRCA2 TP53
15 11.6 CDH1 ERBB2 TP53 VEGFA
16 11.57 BRCA1 ERBB2 PIK3CA TP53
17 11.56 ERBB2 PIK3CA TP53
18 11.42 BRCA1 TP53 VEGFA
19 11.12 CDH1 ERBB2 PIK3CA
20 10.84 ARID1A BRCA1 ERBB2 PIK3CA TP53

GO Terms for Ovarian Cancer 1

Cellular components related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 AREG ARID1A BRCA1 BRCA2 DPH1 ERBB2
2 lateral element GO:0000800 8.96 BRCA1 BRCA2

Biological processes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.89 CEACAM5 ERBB2 HNF1B TP53 VEGFA
2 positive regulation of gene expression GO:0010628 9.85 BRCA1 ERBB2 HNF1B TP53 VEGFA
3 cell proliferation GO:0008283 9.77 AREG BRCA2 DPH1 ERBB2 TP53
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.65 AREG TP53 VEGFA
5 positive regulation of transcription, DNA-templated GO:0045893 9.5 ARID1A BRCA1 BRCA2 CDH1 HNF1B PAX8
6 mesonephric tubule development GO:0072164 9.43 HNF1B PAX8
7 pronephros development GO:0048793 9.4 HNF1B PAX8
8 cellular response to indole-3-methanol GO:0071681 9.32 BRCA1 CDH1
9 chordate embryonic development GO:0043009 9.26 BRCA1 BRCA2
10 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.16 HNF1B PAX8
11 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 BRCA1 BRCA2 TP53

Molecular functions related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.26 BRCA1 HNF1B PAX8 TP53
2 identical protein binding GO:0042802 9.17 BRCA1 BRCA2 CDH1 CEACAM5 ERBB2 TP53

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....